Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma.

Détails

Ressource 1Télécharger: smw.2006.11467.pdf (358.52 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_F68233E85238
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma.
Périodique
Swiss medical weekly
Auteur⸱e⸱s
Trojan A., Tinguely M., Vallet S., Seifert B., Jenni B., Zippelius A., Witzens-Harig M., Mechtersheimer G., Ho A., Goldschmidt H., Jäger D., Boccadoro M., Ladetto M.
ISSN
1424-7860 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
24/06/2006
Peer-reviewed
Oui
Volume
136
Numéro
25-26
Pages
400-403
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.

Mots-clé
Adult, Aged, Aged, 80 and over, Cyclooxygenase 2/metabolism, Disease Progression, Female, Humans, Immunohistochemistry/methods, Male, Middle Aged, Multiple Myeloma/enzymology, Multiple Myeloma/metabolism, Multiple Myeloma/pathology, Proportional Hazards Models, Survival Analysis
Pubmed
Web of science
Création de la notice
16/10/2017 8:32
Dernière modification de la notice
20/08/2019 16:22
Données d'usage